about
The role of drug transporters in the kidney: lessons from tenofovirThe Effect of Gene Variants on Levonorgestrel Pharmacokinetics When Combined With Antiretroviral Therapy Containing Efavirenz or Nevirapine.Pharmacogenetic considerations for HIV treatment in different ethnicities: an update.Pregnancy affects nevirapine pharmacokinetics: evidence from a CYP2B6 genotype-guided observational study.Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics of Efavirenz 400 mg Once Daily During Pregnancy and Post-PartumPharmacokinetics of Efavirenz 400 mg Once Daily Coadministered With Isoniazid and Rifampicin in Human Immunodeficiency Virus-Infected IndividualsA Lower Dose of Efavirenz Can Be Coadministered With Rifampicin and Isoniazid in Tuberculosis PatientsGenetic influence of ABCG2, UGT1A1 and NR1I2 on dolutegravir plasma pharmacokineticsDo genetic variations in proximal tubule transporters influence tenofovir-induced renal dysfunction? An exploratory study in a Ghanaian populationImpact of pharmacogenetics and pregnancy on tenofovir and emtricitabine pharmacokineticsEffect of patient genetics on etonogestrel pharmacokinetics when combined with efavirenz or nevirapine ARTRifampicin effect on intracellular and plasma pharmacokinetics of tenofovir alafenamideMeta-analysis of the effect of CYP2B6, CYP2A6, UGT2B7 and CAR polymorphisms on efavirenz plasma concentrationsPrioritisation of potential anti-SARS-CoV-2 drug repurposing opportunities based on ability to achieve adequate target site concentrations derived from their established human pharmacokineticsDose prediction for repurposing nitazoxanide in SARS-CoV-2 treatment or chemoprophylaxis
P50
Q26866489-467C2EEB-3CB1-4646-B8C3-DA961AAD5052Q38851258-9B349DD5-0B98-4380-89EF-78CBCB7DFE62Q47906608-AB3808A1-D132-4B5B-9820-EA29F3D84C62Q50265016-06C2F5FE-52B3-41F1-A170-85C1DFB2A080Q56910315-FB1AB266-BC11-4D7D-919D-8DE247B2EE8BQ59355041-7AE35044-8C1A-4B32-A5D5-D666962D42CDQ64272805-AC354917-106D-4488-A42B-80E8500D7FD7Q89502911-D51A1E77-C84E-4B8D-9F68-92E7683B2417Q89723623-913EA680-F367-47A3-8170-B02FC8A476ABQ91611772-7FCFF711-AB8A-4401-9A13-0C00600B8D69Q91828901-B6537C69-A6E9-4294-8E65-6FD35158C63BQ91992711-EEA1189B-3D83-44F3-92D9-0C783155E1E5Q92337199-543362AD-FE74-4781-B059-9FB6C3C8E5DBQ95601629-6F47603D-D93D-4E8C-8B6C-5E5EADCD97E1Q95614621-2D22F705-9F66-46F6-88E8-8DE955871E3B
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
M Neary
@ast
M Neary
@en
M Neary
@es
M Neary
@nl
M Neary
@sl
type
label
M Neary
@ast
M Neary
@en
M Neary
@es
M Neary
@nl
M Neary
@sl
prefLabel
M Neary
@ast
M Neary
@en
M Neary
@es
M Neary
@nl
M Neary
@sl
P106
P31
P496
0000-0002-4960-2139